Quommni Technologies was originally conceived in 2017 to develop products for quantifying protein levels and expression in patient samples, especially in vitro. Since then, we pivoted to address the growing problem of infectious and genetic diseases through nucleic acid diagnostics. We then began research and development for our centrifugal microfluidic chip platform (Galaxy Chip) and assay system (D-Qube). In the process, we have accumulated substantial experience, published a study, and obtained patents for our microfluidic system, with additional patents and publications on the way.
Since the beginning, our mission has been to serve those who are in need. Many people around the world suffer from countless illnesses and we believe they deserve the best technologies that modern science can offer. We hope to let them know that a company can care and produce a product which truly and completely satisfies a need. Our team is composed of people who empathize with those that have been discomforted by affliction, and through our ambition and collective knowledge we are devoting ourselves to remedy and ideally prevent their issues with sensitive and accurate diagnostic results.